BLA 125418 · Sanofi Aventis US
Zaltrap
Ziv-Aflibercept · Injection · Vascular Endothelial Growth Factor Inhibitor
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Dec 13, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Aug 3, 2012
Approved uses
2
Original approval plus efficacy supplements
Registered trials
468
132 Phase 3, 39 recruiting
FAERS reports
1,304
1,220 serious, 207 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 6, 2025.
ZALTRAP, in combination with fluorouracil, leucovorin, irinotecan-(FOLFIRI), is indicated for the treatment of patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen. ZALTRAP, a vascular endothelial growth factor inhibitor, in combination with fluorouracil, leucovorin, irinotecan (FOLFIRI), is indicated for the treatment of patients with metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen. ( 1 )
Mechanism: Ziv-aflibercept acts as a soluble receptor that binds to human VEGF-A (equilibrium dissociation constant K D of 0.5 pM for VEGF-A 165 and 0.36 pM for VEGF-A 121 ), to human VEGF-B (K D of 1.92 pM), and to human PlGF (K D of 39 pM for PlGF-2). By binding to these endogenous ligands, ziv-aflibercept can inhibit the binding and activation of their cognate receptors. This inhibition can result in decreased neovascularization and decreased vascular permeability. In animals, ziv-aflibercept was shown to inhibit the proliferation of endothelial cells, thereby inhibiting the growth of new blood...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 17, 2015 Supplement 33 · Efficacy Letter
- Aug 3, 2012 Original approval · Type 1 - New Molecular Entity · priority review NovelSummary ReviewLabelReview
1 products under this application
- ZALTRAP · ZIV-AFLIBERCEPT 4MG · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ziv-Aflibercept" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of RTH258 Versus Aflibercept - Study 1Pivotal-lookingCompleted
Alcon ResearchIndustry
NCT02307682 · 1,775 participants · Start Dec 8, 2014 · Primary completion Apr 22, 2017
Drug: Brolucizumab ophthalmic solution; Aflibercept ophthalmic solution · For: Neovascular Age-Related Macular Degeneration; Choroidal Neovascularization
Sites: Fort Worth, Texas
- Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)Pivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00637377 · 1,240 participants · Start Apr 2008 · Primary completion Sep 2010
Drug: Ranibizumab; Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) and 2 more · For: Macular Degeneration
Sites: Buenos Aires, Argentina; Córdoba, Argentina; Rosario, Argentina · 189 sites in all
- Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based RegimenPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00561470 · 1,226 participants · Start Nov 2007 · Primary completion Feb 2011
Drug: Placebo; Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) and 2 more · For: Colorectal Neoplasms; Neoplasm Metastasis
Sites: Birmingham, Alabama; Muscle Shoals, Alabama; Hot Springs, Arizona · 221 sites in all
- Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate CancerPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00519285 · 1,224 participants · Start Aug 2007 · Primary completion Apr 2012
Drug: Aflibercept; Placebo (for aflibercept) and 2 more · For: Prostatic Neoplasms; Neoplasm Metastasis
Sites: Bridgewater, New Jersey; Buenos Aires, Argentina; Macquarie Park, Australia · 31 sites in all
- Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)Pivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT00509795 · 1,217 participants · Start Aug 2007 · Primary completion Sep 2010
Drug: ranibizumab; aflibercept injection (VEGF Trap-Eye, BAY86-5321) and 2 more · For: Macular Degeneration
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 188 sites in all
- Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)Pivotal-lookingTerminated
Chengdu Kanghong Biotech Co., Ltd.Industry
NCT03630952 · 1,157 participants · Start Dec 21, 2018 · Primary completion Sep 10, 2020
Drug: 0.5 mg Conbercept Intravitreal Injection; 1.0 mg Conbercept Intravitreal Injection and 1 more · For: Neovascular Age-related Macular Degeneration
Sites: Phoenix, Arizona; Springdale, Arkansas; Arcadia, California · 154 sites in all
- Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)Pivotal-lookingTerminated
Chengdu Kanghong Biotech Co., Ltd.Industry
NCT03577899 · 1,157 participants · Start Sep 25, 2018 · Primary completion Sep 25, 2020
Drug: 0.5 mg Conbercept Intravitreal Injection; 1.0 mg Conbercept Intravitreal Injection and 1 more · For: Neovascular Age-related Macular Degeneration
Sites: Phoenix, Arizona; Tucson, Arizona; Beverly Hills, California · 179 sites in all
- A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)Pivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06491914 · 1,126 participants · Start Jul 24, 2024 · Primary completion Aug 26, 2025
Drug: Aflibercept 8 mg · For: Neovascular Age-Related Macular Degeneration; Diabetic Macular Edema
Sites: Arcadia, California; Bakersfield, California; Beverly Hills, California · 54 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea178
- hypertension137
- neutropenia105
- asthenia73
- vomiting68
- proteinuria64
- death61
- nausea59
- disease progression49
- fatigue48
- stomatitis43
- abdominal pain42
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 20 |
| 2013 | 120 |
| 2014 | 114 |
| 2015 | 105 |
| 2016 | 109 |
| 2017 | 115 |
| 2018 | 258 |
| 2019 | 184 |
| 2020 | 92 |
| 2021 | 28 |
| 2022 | 21 |
| 2023 | 41 |
| 2024 | 64 |
| 2025 | 19 |
| 2026 | 14 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zaltrap (Ziv-Aflibercept)
2024 spending
$69K
Beneficiaries
n/a
13 claims
Per beneficiary
n/a
$390.72 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $265,301 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $68,650 |
Part B: Zaltrap (Ziv-Aflibercept) · HCPCS J9400
2024 spending
$255K
Beneficiaries
25
110 claims
Per beneficiary
$10,183
2024 ASP limit $6.89 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,827,500 |
| 2021 | $1,517,400 |
| 2022 | $1,360,531 |
| 2023 | $683,080 |
| 2024 | $254,571 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ziv-aflibercept versus bevacizumab administration prior to diabetic vitrectomy: a randomised and controlled trial.
Aleman I, Castillo Velazquez J, Rush SW, et al. · Br J Ophthalmol 2019 · Comparative Study, Randomized Controlled Trial
- Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Van Cutsem E, Tabernero J, Lakomy R, et al. · J Clin Oncol 2012 · Clinical Trial, Phase III, Randomized Controlled Trial
- A Phase II Trial of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors.
Halperin DM, Lee JJ, Ng CS, et al. · Pancreas 2019 · Clinical Trial, Phase II, Research Support, N.I.H., Extramural
- A Phase II Study of Ziv-Aflibercept in Patients With Advanced Extrapancreatic Neuroendocrine Tumors.
Perez K, Kulke MH, Horick NK, et al. · Pancreas 2022 · Clinical Trial, Phase II
- Efficacy and safety of intravitreal Ziv-Aflibercept for the treatment of macular edema: A systematic review and meta-analysis.
Munayco-Guillén F, García-Roa M, Vázquez-Membrillo M, et al. · Arch Soc Esp Oftalmol (Engl Ed) 2026 · Systematic Review, Meta-Analysis
- Hemorrhagic events in cancer patients treated with aflibercept: a meta-analysis.
Peng L, Bu Z, Zhou Y, et al. · Tumour Biol 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.